Description
Moderna, a leader in mRNA medicine, has partnered with OpenAI to accelerate the development of life-saving treatments. This collaboration began in early 2023, focusing on deploying ChatGPT Enterprise to thousands of employees across the company. By integrating AI into various functions, Moderna aims to create novel use cases that enhance the impact of every team.
With over a decade of experience at the intersection of science, technology, and health, Moderna's mission is to maximize its positive impact on patients. The company is known for its COVID-19 vaccine and is now leveraging its platform to bring up to 15 new products to market in the next five years, including vaccines against RSV and individualized cancer treatments. Moderna's approach is people-centric and technology-forward, constantly testing new innovations to enhance human capacity and clinical performance.
Moderna's objective is to achieve 100% adoption and proficiency of generative AI among its employees with access to digital solutions within six months. The company believes in collective intelligence and has implemented a transformation program that includes individual, collective, and structural change management initiatives. These initiatives involve in-depth research, training programs, and an AI prompt contest to identify top AI users within the organization.
The launch of an internal AI chatbot tool, mChat, marked an early success, with over 80% employee adoption. Following this, Moderna decided to adopt ChatGPT Enterprise, which outperformed mChat in user satisfaction. The results have been impressive, with 750 GPTs created within two months of adoption and each user averaging 120 conversations per week.
One notable application of ChatGPT Enterprise is the Dose ID GPT, which assists clinical teams in analyzing data and making informed decisions regarding vaccine dosing. Additionally, the legal team has achieved 100% adoption of ChatGPT Enterprise, allowing them to focus on impactful patient-related matters. The corporate brand team has also utilized AI to enhance communication strategies across various audiences.
As Moderna aims to launch multiple products in the coming years, AI is seen as a crucial component for success. The company believes it can operate efficiently with a smaller workforce by leveraging technology and AI to maximize its impact on patients. Moderna's culture of learning and curiosity positions it well to adopt new technologies and build AI-first solutions, ultimately leading to better patient outcomes.
Key Takeaways
Partnership with OpenAI
Deployment of ChatGPT Enterprise
100% adoption goal for generative AI
750 GPTs created within two months
80% employee adoption of mChat
Dose ID GPT for clinical data analysis
AI tools for legal and corporate branding
Focus on patient outcomes
What This Case Study Demonstrates
- Clinical Data Analysis
- Legal Document Summarization
- Corporate Communication
- Employee Training
- Innovation in Product Development
